en · de · es
melanotan-2-notes.peptides3081.com › Wiki › Background And Mechanism Of Melanotan-2 — Complete Guide

Background And Mechanism Of Melanotan-2 — Complete Guide

By Editorial Desk · published 2026-01-13 · last reviewed 2026-02-20 · Wiki

If you have been reading about MC1R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-02-20. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of Melanotan-2

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Storage, Verification and Regulatory Status

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.

Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.

Melanotan-2 at a glance

PropertyValueNotes
Compound classSynthetic cyclic heptapeptideAlpha-MSH analogue containing a D-phenylalanine residue
Molecular formulaC50H69N15O9Average molecular mass approximately 1024.2 g/mol
AppearanceWhite to off-white lyophilised powderNormally supplied as a freeze-dried solid in a sealed vial
SolubilityFreely soluble in water and polar solventsDissolves readily in aqueous buffers and in alcohol-water mixtures
Receptor targetsMC1R, MC3R, MC4R, MC5RActs as a non-selective melanocortin receptor agonist

Melanotan-2 Identity And Regulatory Status

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Related pages on this site

Handling, Storage and Analytical Control

Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.

Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.

Melanotan-2 Identity and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Regulatory Status and Literature Discussion

Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.

Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.

Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.

Background from the literature

Works by or about Frederick Banting at the Internet Archive Banting House National Historic Site (Archived January 17, 2021, at the Wayback Machine) Frederick Banting on Nobelprize.org including the Nobel Lecture on September 15, 1925, "Diabetes and Insulin" Ontario Plaques – The Discovery of Insulin (Archived December 22, 2015, at the Wayback Machine) CBC Digital Archives – Chasing a Cure for Diabetes Simcoe County Archives – "Sir Frederick Banting" Famous Canadian Physicians: Sir Frederick Banting at Library and Archives Canada World Diabetes Day on Banting's Birthday, November 14 1928 A.Y. Jackson and Frederick Banting – NWT Historical Timeline, Prince of Wales Northern Heritage Centre Frederick Banting Papers, Thomas Fisher Rare Book Library Archived March 14, 2012, at the Wayback Machine The Discovery and Early Development of Insulin Digital Collection, Toronto

=== Oxidation-reduction === A reducing sugar is one that reduces another compound and is itself oxidized; that is, the carbonyl carbon of the sugar is oxidized to a carboxyl group. A sugar is classified as a reducing sugar only if it has an open-chain form with an aldehyde group or a free hemiacetal group.

== Epidemiology == Globally, silicosis resulted in 46,000 deaths in 2013, down from 55,000 deaths in 1990. Despite this downward trend in total deaths, silicosis remains a significant global health threat. It is a preventable, incurable, and sometimes fatal disease.

Malaysia's legal system is based on common law. Although the judiciary is theoretically independent, its independence has been called into question and the appointment of judges lacks accountability and transparency. The highest court in the judicial system is the Federal Court, followed by the Court of Appeal and two high courts, one for Peninsular Malaysia and one for East Malaysia. Malaysia also has a special court to hear cases brought by or against royalty. Race is a significant force in politics. Affirmative actions such as the New Economic Policy and the National Development Policy which superseded it, were implemented to advance the standing of the bumiputera, consisting of Malays and the indigenous tribes who are considered the original inhabitants of Malaysia, over non-bumiputera such as Malaysian Chinese and Malaysian Indians. These policies provide preferential treatment to bumiputera in employment, education, scholarships, business, and access to cheaper housing and assisted savings. However, it has generated greater interethnic resentment. There is ongoing debate over whether the laws and society of Malaysia should reflect Islamism or secularism. Islamic criminal laws passed by the Pan-Malaysian Islamic Party with the support of UMNO state assemblymen in the state legislative assembly of Kelantan have been unenforced by the federal government on the basis that criminal laws are the responsibility of the federal government.

Sources: en.wikipedia.org

Further detail

Nuclide column Nuclide identifiers are given by their atomic mass number A and the symbol for the corresponding chemical element (corresponding to the unique proton number). In the cases that this is not the ground state, this is indicated by a m for metastable appended to the mass number; the conventional numbers are further appended to distinguish multiple metastable states but '1' is omitted if the others are much less stable.

Saliva moistens and softens food, and along with the chewing action of the teeth, transforms the food into a smooth bolus. The bolus is further helped by the lubrication provided by the saliva in its passage from the mouth into the esophagus. Also of importance is the presence in saliva of the digestive enzymes amylase and lipase. Amylase starts to work on the starch in carbohydrates, breaking it down into the simple sugars of maltose and dextrose that can be further broken down in the small intestine. Saliva in the mouth can account for 30% of this initial starch digestion. Lipase starts to work on breaking down fats. Lipase is further produced in the pancreas where it is released to continue this digestion of fats. The presence of salivary lipase is of prime importance in young babies whose pancreatic lipase has yet to be developed. As well as its role in supplying digestive enzymes, saliva has a cleansing action for the teeth and mouth. It also has an immunological role in supplying antibodies to the system, such as immunoglobulin A. This is seen to be key in preventing infections of the salivary glands, importantly that of parotitis. Saliva also contains a glycoprotein called haptocorrin which is a binding protein to vitamin B12. It binds with the vitamin in order to carry it safely through the acidic content of the stomach. When it reaches the duodenum, pancreatic enzymes break down the glycoprotein and free the vitamin which then binds with intrinsic factor.

=== Microtox Omni software === The Microtox Omni software was developed by Azur Environmental and allows users of the Microtox Model 500 analyser to run tests, visualize data, calculate statistics and generate reports. This program contains a set of templates for all of the commonly used toxicity tests and allows you to modify or add to the provided templates. The modification of these templates allows for the production of new test formats not originally included with the software. The test templates that are included in this software define all of the parameters for a particular test method. This program calculates the most efficient way of setting up the desired test on the Model 500 Analyser. A test tutor is also included with Microsoft Omni that gives listed instructions on how to set up and run the test of interest. This software allows users to load files from previous versions of the Microtox DOS Software and also gives users the ability to save new data in that original format. A database is included in this software that grants users to access data from a number of other users and test sites, allowing for a comparison of data and trend changes over time. Microtox Omni can be used with any number of databases.

== Epidemiology == The prevalence of PAH is estimated to be 25 cases per 1 million people in Western countries. PAH is more common in women, the ratio of females to males affected by PAH is 1.7 to 1. Others have estimated that the prevalence of PAH related to congenital heart disease is 25 cases per 1 million people.

For example, the pattern may be 10 press ups, then two minutes rest, 10 press ups, then two minutes rest etc. The ability to recover during an exercise (active recovery), during a training session, and resting between training sessions are all of fundamental importance in strength training. If recovery cannot take place then fatigue may occur leading to worse performance and an increased chance of injury.

Sources: en.wikipedia.org

Background from the literature

As of 2018, research has paid insufficient attention to the potential adverse effects of carbohydrate restricted dieting, particularly for micronutrient sufficiency, bone health and cancer risk. One low-quality meta-analysis reported that adverse effects could include "constipation, headache, halitosis, muscle cramps and general weakness". In a comprehensive systematic review of 2018, Churuangsuk and colleagues reported that other case reports give rise to concerns of other potential risks of low-carbohydrate dieting including hyperosmolar coma, Wernicke's encephalopathy, optic neuropathy from thiamine deficiency, acute coronary syndrome and anxiety disorder. Significantly restricting the proportion of carbohydrate in diet risks causing malnutrition, and can make it difficult to get enough dietary fiber to stay healthy. As of 2014, it appeared that with respect to the risk of death for people with cardiovascular disease, the kind of carbohydrates consumed are important; diets relatively higher in fiber and whole grains lead to reduced risk of death from cardiovascular disease compared to diets high in refined grains.

=== Recovery and outcomes === Blepharoplasty is typically performed as an outpatient procedure and may take one to three hours depending on the extent of surgery. Postoperative swelling and bruising are common and generally resolve over several weeks. Supportive measures such as cold compresses and head elevation are often recommended during the early recovery period. Incisions are typically closed with fine sutures, which may be removed within several days in the case of external approaches or may be absorbable depending on the technique used. Suture management and wound care play a role in minimizing scarring and supporting proper healing. Results vary based on patient anatomy and surgical technique, but generally include improvement in eyelid contour, reduction of excess tissue, and a more defined eyelid–cheek junction.

=== Initial hospital management === The clinician must protect the patient against hypotension, kidney failure, acidosis, hyperkalemia and hypocalcemia. Admission to an intensive care unit, preferably one experienced in trauma medicine, may be appropriate; even well-seeming patients need observation. Open wounds should be treated as surgically appropriate, with debridement, antibiotics and tetanus toxoid; ice should be applied to injured areas. Breathing and circulation must be checked and the patient should be given oxygen if eligible. Oral or intravenous fluids must be given depending on the measured amounts of electrolytes, arterial blood gases, and muscle enzymes. Intravenous hydration of up to 1.5 L/h should continue to prevent hypotension. A urinary output of at least 300 mL/h should be maintained with IV fluids and mannitol, and hemodialysis considered if an increase in urine is not achieved. Intravenous sodium bicarbonate should be used to keep the urine pH at 6.5 or greater, to prevent myoglobin and uric acid deposition in kidneys. To prevent hyperkalemia/hypocalcemia, consider the following adult doses:

=== Infectious diseases === Imaging infections with molecular imaging technologies can improve diagnosis and treatment follow-up. Clinically, PET has been widely used to image bacterial infections using FDG to identify the infection-associated inflammatory response. Three different PET contrast agents have been developed to image bacterial infections in vivo are [18F]maltose, [18F]maltohexaose, and [18F]2-fluorodeoxysorbitol (FDS). FDS has the added benefit of being able to target only Enterobacteriaceae.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 a natural hormone?

No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.

Has it been approved for any medical use?

No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.

Which receptor matters most for pigmentation?

Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.

How should the powder be stored?

The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.

Network